April 4 (Reuters) - Health Canada:
* INFORMATION UPDATE - HEALTH CANADA ADVISES ALLERGAN OF ITS INTENT TO SUSPEND ITS LICENCES FOR BIOCELL BREAST IMPLANTS AS A PRECAUTIONARY MEASURE
* HEALTH CANADA - AS OF APRIL 4, BEEN NOTIFIED OF 28 CONFIRMED CANADIAN CASES OF BIA-ALCL, OF WHICH 24 (86%) INVOLVE ALLERGAN'S BIOCELL BREAST IMPLANT
* HEALTH CANADA - REVIEWING INFORMATION ON SAFETY OF TEXTURED BREAST IMPLANTS, INCLUDES ANY NEW EVIDENCE PROVIDED BY ALLERGAN IN NEXT 15 CALENDAR DAYS
* HEALTH CANADA - ENGAGING INTERNATIONALLY ON SAFETY OF BREAST IMPLANTS, INCLUDING RECENT MEETINGS WITH FRENCH REGULATOR AND FDA
* HEALTH CANADA - IF SATISFACTORY RESPONSE IS NOT RECEIVED FROM ALLERGAN IN NEXT 15 CALENDAR DAYS, INTENTION TO SUSPEND BIOCELL MEDICAL DEVICE LICENCES
* HEALTH CANADA - IN CONTACT WITH FRANCE ABOUT ITS DECISION TODAY TO SUSPEND SALE OF MACRO-TEXTURED BREAST IMPLANTS, POLYURETHANE-COATED BREAST IMPLANTS
* HEALTH CANADA - ENTIRETY OF ITS SAFETY REVIEW OF BREAST IMPLANTS AND BIA-ALCL WILL BE AVAILABLE BY END OF APRIL
* HEALTH CANADA SAYS STARTED A SECOND SAFETY REVIEW ON SYSTEMIC SYMPTOMS ASSOCIATED WITH BREAST IMPLANTS
* HEALTH CANADA - RESULTS OF THE SECOND SAFETY REVIEW WILL BE MADE PUBLIC IN SUMMER 2019.